The Recall Desk
Agency classClass IIOur severity:SevereFDA (Drugs)·D-0983-2020·Announced 2020-03-11

Axia Pharmaceutical Recalls Testosterone Cypionate Injection Due to Sterility Concerns

Axia Pharmaceutical is recalling specific lots of Testosterone Cypionate Injection because the company cannot guarantee the product is sterile.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable medication, which poses a significant risk of serious injury or infection.

Plain-English summary

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical is recalling specific lots of Testosterone Cypionate Injection, 200 mg/mL, 10 mL multi-dose vials. The recall was initiated because the company lacks assurance of the sterility of the affected product.

The affected product is distributed nationwide in the U.S., as well as in Puerto Rico, Barbados, and the Dominican Republic. The recall covers thirteen specific lots with expiration dates ranging from June 2020 to January 2021.

Healthcare providers and patients should stop using the affected lots and contact the manufacturer for further instructions or to arrange for a return.

The recalled product

Product
Testosterone Cypionate Injection,TESTOSTERONE CYP IN GRAPESEED OIL [10ML] 200 MG/ML INJECTABLE, For IM Use, 10 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0530-1
Manufacturer
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
Category
Drug — Injectable Steroids
Hazard

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

  • Lot #: 03252019+51850
  • Exp 7/6/2020
  • 04252019+52098
  • Exp 6/29/2020
  • 04292019+52108
  • 05012019+52132
  • Exp 10/22/2020
  • 05202019+52268
  • Exp 11/10/2020
  • 05222019+52290
  • 05302019+52334
  • Exp 11/20/2020
  • 07082019+52594
  • Exp 12/29/2020
  • 07102019+52619
  • 07292019+52762
  • Exp 8/12/2020
  • 07312019+52778
  • 09102019+52898
  • Exp 1/16/2021

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically:

Part of a larger recall action

This product is one of 63 recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 63 products in this recall →

Related recalls

Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical

See all →

Same hazard · sterility

See all →

Similar recalls